Schrödinger, Inc.

NASDAQ:SDGR

Medical - Healthcare Information Services

Healthcare
$27.20 +0.01%

+$0.00 today

Market cap
$1.79B
Beta
1.64
P/E (TTM)
-11.1
EPS (TTM)
-$1.40
52W Low $10.95High $23.75

Volume 1.18M

Average 1.35M

SDGR Capital Expenditures

Cash spent on property, plant, equipment, and other long-term assets.

Schrödinger, Inc.NASDAQ: SDGR

Capital Expenditures · Q3 FY2026 · quarter ended Sep 2026

Capital expenditures growth accelerates

Q3 FY2026 capital expenditures of $1.29M (cash outflow) rose 162.5% year over year, ahead of the +84.7% change in trailing-twelve-month capital expenditures. Sequentially, it rose 256.1% from the prior quarter. Over 3 fiscal years it compounded at -43.5% a year.

Context

  • Capital expenditures amounted to 0.6% of revenue in FY2025, down 3.0 pp from a year earlier.
  • Capital expenditures grew in size in 1 of the last 3 fiscal years.
  • FY2025 was the smallest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth of +162.5% holds above the trailing-twelve-month pace of +84.7%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterSep 2026
-$1.29M+256.1% QoQ
Last fiscal yearDec 2025
-$1.44M-80.3% YoY
LTMSep 2026
-$4.2M+84.7% YoY
Capital Expenditures past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+162.5%——
1 year-80.3%——
3-year CAGR-43.5%——
5-year CAGR——
10-year CAGR——

Capital Expenditures history

USD · from the cash flow

Latest · FY2025
(1.44M) USD
Year-over-year change
+80.3%

Capital Expenditures vs competitors

How SDGR compares with its peers on the latest reported figures

  • Peers report in different currencies, so capital expenditures is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +84.7% is the 2nd highest of 9, against a peer median of -35.1%.
  • Capital expenditures amounts to 1.6% of revenue for SDGR, versus a peer median of 1.9%.
SDGR Competitors
Capital Expenditures for SDGR and competitors
Company Period LTM YoY 3-year CAGR% of revenue
VEEVVeeva Systems Inc.LTM Jul 2026$23.11M USD+9.0%+29.2%0.7%
ABCLAbCellera Biologics Inc.LTM Sep 2026$17.42M USD-64.1%-16.2%25.7%
SDGRSchrödinger, Inc.LTM Sep 2026$4.2M USD+84.7%-43.5%1.6%
GENBGenerate Biomedicines, Inc.FY2025$3.51M USD+1.9%—11.0%
CERTCertara, Inc.LTM Mar 2026$1.79M USD-85.3%+7.2%0.4%
SLPSimulations Plus, Inc.LTM Feb 2026$1.51M USD-17.8%-43.6%1.9%
HYFTMindWalk Holdings Corp.LTM Jan 2026CA$745.58K CAD-52.4%-14.0%4.1%
LTRNLantern Pharma Inc.LTM Mar 2026$567 USD-95.1%-60.5%—
RLAYRelay Therapeutics, Inc.LTM Jun 2026$0 USD+100.0%-64.4%0.0%
Peer median (excluding SDGR) —-35.1%-16.2%1.9%

Competitors are the stored peer set for SDGR. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(101.22M)(149.19M)40.72M(187.12M)(103.27M)
Depreciation & Amortization2.85M4.34M5.55M6.16M6.02M
Deferred Income Tax00000
Stock-Based Compensation26.49M39.63M47.84M49.9M43M
Change in Working Capital4.68M(21.38M)(22.55M)(13.04M)118.17M
Accounts Receivables(5.51M)(27.95M)(20.03M)(166.22M)150.94M
Inventory00000
Accounts Payables(411K)1.18M7.32M(6.12M)908K
Other Working Capital10.6M5.39M(9.85M)159.3M(33.68M)
Other Non-Cash Items(3.46M)6.91M(208.29M)(13.27M)(50.02M)
Operating Cash Flow(70.67M)(119.68M)(136.73M)(157.37M)13.9M
Capital Expenditures(7.17M)(8.01M)(13.4M)(7.31M)(1.44M)
Acquisitions (Net)0(7.03M)(4.13M)45.73M0
Purchases of Investments(418.5M)(271.47M)(320.62M)(251.34M)(312.96M)
Sales of Investments408.48M364.71M383.97M361.76M372.3M
Other Investing Activities375K11.83M147.21M00
Investing Cash Flow(16.81M)90.02M193.03M148.84M57.9M
Debt Repayment00(19K)(58K)(58K)
Common Stock Issued0008.87M2.99M
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities7.95M2.11M9.07M1.31M0
Financing Cash Flow7.95M2.11M9.05M10.12M2.93M
Effect of Forex Changes00000
Net Change in Cash(79.53M)(27.55M)65.35M1.59M74.73M
Free Cash Flow(77.84M)(127.7M)(150.14M)(164.68M)12.46M

Schrödinger, Inc.

NASDAQ:SDGR

Intrinsic Alpha fair value

Locked

Current Price

$27.20

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.